PolyPid awards 46,000 stock options to COO

PolyPid Ltd. granted Chief Operating Officer – US Ori Warshavsky a stock option for 46,000 Ordinary Shares with an exercise price of 4.4600 per share.

Accepted by SEC EDGAR 07/17/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PolyPid Ltd. granted Chief Operating Officer – US Ori Warshavsky a stock option for 46,000 Ordinary Shares with an exercise price of 4.4600 per share. The option vests quarterly from May 11, 2026 through May 11, 2030 and expires on May 11, 2036.

Insider Trade Summary

Grant/Award: 46,000 shares

Grant/Award 1 txn

Insider Warshavsky Ori

Role Chief Operating Officer - US

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	46,000	$4.46	$205K

Holdings After Transaction: Stock option (right to buy) — 46,000 contracts (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 46,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.

Key Figures

Options granted: 46000.0000 options Exercise price: 4.4600 Underlying shares: 46000.0000 Ordinary Shares +3 more

6 metrics

Options granted 46000.0000 options Stock option award to COO-US on 2026-05-11

Exercise price 4.4600 Exercise price per option for the 46,000-option grant

Underlying shares 46000.0000 Ordinary Shares Shares issuable upon exercise of the reported stock options

Options after transaction 46000.0000 options Total derivative securities held from this award following the transaction

Vesting period 2026-05-11 to 2030-05-11 Options vest quarterly over this period

Expiration date 2036-05-11 Expiration of the granted stock options

Key Terms

Stock option (right to buy), Ordinary Shares, vest on a quarterly basis

3 terms

Stock option (right to buy) financial

"Security title reported as Stock option (right to buy) for 46,000"

Ordinary Shares financial

"Underlying security title identified as Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vest on a quarterly basis financial

"The options vest on a quarterly basis beginning May 11, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PolyPid (PYPD) report for Ori Warshavsky?

PolyPid reported a grant of 46,000 stock options to COO-US Ori Warshavsky. Each option covers one Ordinary Share with an exercise price of 4.4600, vesting quarterly from May 11, 2026 to May 11, 2030 and expiring in 2036.

How many stock options were granted to PolyPid (PYPD) COO Ori Warshavsky?

Ori Warshavsky received 46,000 stock options in this award. The options are exercisable into 46,000 Ordinary Shares at an exercise price of 4.4600 per share, with all 46,000 options reported as held following the transaction.

What are the vesting terms of the new PolyPid (PYPD) stock options?

The options vest on a quarterly basis beginning May 11, 2026. Vesting continues through May 11, 2030, spreading the 46,000-option award over multiple quarterly installments rather than vesting all at once on the grant date.

When do Ori Warshavsky’s PolyPid (PYPD) stock options expire?

The granted stock options expire on May 11, 2036. Warshavsky can exercise the vested portions between the initial vesting date in 2026 and this expiration date, subject to the company’s equity plan and any applicable service conditions.

At what exercise price were the PolyPid (PYPD) options granted to the COO?

The options were granted with an exercise price of 4.4600 per share. This price applies to each of the 46,000 options covering Ordinary Shares and remains fixed for the life of the option through its May 11, 2036 expiration.

Were the PolyPid (PYPD) COO’s options granted under a Rule 10b5-1 plan?

The report’s Rule 10b5-1 checkbox is not marked as affirmative. There is no accompanying footnote indicating that this option grant was made under a pre-arranged Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warshavsky Ori

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer - US

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	05/11/2026		A		46,000		08/11/2026(1)	05/11/2036	Ordinary Shares	46,000	$4.46	46,000	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.

	/s/ Warshavsky Ori	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)